DECLARETIMI 58 study on an antidiabetic agent of dapagliflozin

The results of DECLARE, the largest clinical study to evaluate a new clbad of type 2 antidiabetic drugs called "SGLT-2 inhibitors" and presented at the American Heart Association conference in 2018, show that the new dapagliflozin focus reduces the risk of hospitalization. Due to heart failure or death from cardiovascular disease 17 percent, it helps to achieve positive results with regard to kidney failure and its level of safety is good.

"Doctors have always focused on reducing blood sugar levels in people with diabetes, but type 2 diabetes makes them prone to the complications that lead to diabetes," said Dr. Paula. Attallah, president of the Lebanese Association of Endocrinology, Diabetes and Obesity. Other diseases, including heart failure, which means that we follow very closely the lowering of blood sugar levels. "

The study involved approximately 17,160 patients with type 2 diabetes in 33 countries with multiple risk factors (60%), such as blood lipids, high blood pressure or smoking, and confirmed cardiovascular disease (40%). Followed by a 4.2 year follow-up, the largest of its clbad so far, the longest in patient follow-up and the most extensive in terms of representation of this group of patients.

"This study is unique because it is the first drug in its category to evaluate hospitalization for heart failure or death by CVD," said Dr. Fadi Haddad, former president of the Lebanese Society of Internal Medicine. .

According to estimates, the number of diabetic patients in Lebanon has reached 8% between 20 and 79 years, ie 585,400 people in this age group.